PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33899926-5	2021	Tofacitinib down-regulated inflammatory cytokines by stimulated B (IL-6 and TNF-alpha) and T (IFN-gamma, IL-17, or TNF-alpha) cells in the short term while a significant reduction of IL-17 and IL-6 levels in PBMC supernatant was also observed.	tofacitinib	0-11	interleukin 17A	Homo sapiens	105-110	
33119735-6	2021	Of note, IL-17A deficiency abolished the skin phenotype and treatment using the JAK inhibitor tofacitinib not only prevented onset, but also improved the skin manifestations even after onset.	tofacitinib	94-105	interleukin 17A	Homo sapiens	9-15	
33899926-5	2021	Tofacitinib down-regulated inflammatory cytokines by stimulated B (IL-6 and TNF-alpha) and T (IFN-gamma, IL-17, or TNF-alpha) cells in the short term while a significant reduction of IL-17 and IL-6 levels in PBMC supernatant was also observed.	tofacitinib	0-11	interleukin 17A	Homo sapiens	183-188	
32808031-9	2020	Thus, our findings suggest that tofacitinib is quite effective in protecting from colitis by inhibition of a bundle of T cell derived cytokines like IL-5, IL-6, IL-9, IL-13 and IL-17A.	tofacitinib	32-43	interleukin 17A	Homo sapiens	177-183	
32783069-8	2021	RESULTS: Stimulation with IL-17A induced STAT3 phosphorylation, which was inhibited by the pretreatment with JAK2 inhibitor AZD1480 or JAK1/3 inhibitor tofacitinib.	tofacitinib	152-163	interleukin 17A	Homo sapiens	26-32	
29748971-0	2018	Association between serum interleukin-17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis.	tofacitinib	67-78	interleukin 17A	Homo sapiens	26-41	
31780862-6	2019	Serum IL-35 levels were significantly increased and serum levels of TNF-alpha, IL-17, IL-6, and IFN-gamma were significantly reduced in response to tofacitinib since week 4.	tofacitinib	148-159	interleukin 17A	Homo sapiens	79-84	
29748971-5	2018	AIM: To evaluate correlations between circulating IL-17A and clinical efficacy in patients with psoriasis treated with tofacitinib or etanercept.	tofacitinib	119-130	interleukin 17A	Homo sapiens	50-56	
24342887-13	2014	Further, tofacitinib treatment twice per day significantly decreased the conjunctival expression of IL-17A and significantly increased the conjunctival expression of FoxP3.	tofacitinib	9-20	interleukin 17A	Homo sapiens	100-106	
28994166-10	2017	Tofacitinib suppresses the expression of IL-23, IL-17A, IL-17F, and IL-22 receptors during the stimulation of lymphocytes.	tofacitinib	0-11	interleukin 17A	Homo sapiens	48-54	
22147632-0	2012	The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-gamma and interleukin-17 production by human CD4+ T cells.	tofacitinib	18-29	interleukin 17A	Homo sapiens	93-107	
22147632-5	2012	RESULTS: Tofacitinib treatment of CD4+ T cells originating from synovium and peripheral blood inhibited the production of interleukin-17 (IL-17) and interferon-gamma (IFNgamma) in a dose-dependent manner, affecting both proliferation and transcription, but had no effect on IL-6 and IL-8 production.	tofacitinib	9-20	interleukin 17A	Homo sapiens	122-136	
22147632-5	2012	RESULTS: Tofacitinib treatment of CD4+ T cells originating from synovium and peripheral blood inhibited the production of interleukin-17 (IL-17) and interferon-gamma (IFNgamma) in a dose-dependent manner, affecting both proliferation and transcription, but had no effect on IL-6 and IL-8 production.	tofacitinib	9-20	interleukin 17A	Homo sapiens	138-143	
22460142-5	2012	In vitro experiments indicated that the effects of tofacitinib were mediated through suppression of interleukin 17 (IL-17) and interferon gamma production and proliferation of CD4 T cells, presumably Th1 and Th17.	tofacitinib	51-62	interleukin 17A	Homo sapiens	100-114	
22460142-5	2012	In vitro experiments indicated that the effects of tofacitinib were mediated through suppression of interleukin 17 (IL-17) and interferon gamma production and proliferation of CD4 T cells, presumably Th1 and Th17.	tofacitinib	51-62	interleukin 17A	Homo sapiens	116-121	
22607938-12	2012	Several other cytokines and inflammation markers in tears, including MMP-9, IL-15, IL-17A, and IL-12p70, were markedly reduced in the tofacitinib 0.005% QD group but not the vehicle group.	tofacitinib	134-145	interleukin 17A	Homo sapiens	83-89	
22147632-9	2012	CONCLUSION: Tofacitinib directly suppressed the production of IL-17 and IFNgamma and the proliferation of CD4+ T cells, resulting in inhibition of IL-6 production by RASFs and IL-8 production by CD14+ cells and decreased cartilage destruction.	tofacitinib	12-23	interleukin 17A	Homo sapiens	62-80	
20965150-5	2010	CP-690550 efficiently inhibited IL-17 production from memory T cells in vitro and partly suppressed infarct volume increase after I/R.	tofacitinib	0-9	interleukin 17A	Homo sapiens	32-37